CPT® Code 81221

The CPT® Code 81221 pertains to the molecular genetic testing of the CFTR (cystic fibrosis transmembrane conductance regulator) gene, specifically focusing on known familial variants. This gene, located on chromosome 7, is crucial for encoding the CFTR protein, which functions as a chloride channel in epithelial cells. These cells are found in various organs, including the lungs, liver, pancreas, digestive tract, reproductive organs, and sweat glands. Mutations in the CFTR gene disrupt the normal movement of salt and water across cell membranes, leading to the production of thick, sticky mucus. This mucus can obstruct airways and glands, resulting in the hallmark symptoms of cystic fibrosis, a common autosomal recessive disorder, particularly among Caucasians and Ashkenazi Jewish populations. Individuals who inherit a mutated CFTR gene from both parents may exhibit a range of symptoms, from mild to severe, depending on the specific mutations present. Those who inherit a mutation from only one parent are considered carriers and typically do not show symptoms. The severity of cystic fibrosis can be influenced by whether the mutations are heterozygous (different mutations on each gene) or homozygous (the same mutation on both genes). For instance, the homozygous pairing of the del508F mutation is associated with more severe disease manifestations. Cystic fibrosis significantly impacts pulmonary function, with respiratory infections being a leading cause of morbidity and mortality, often resulting in respiratory failure. Additionally, pancreatic insufficiency occurs in approximately 85% of cases, and other complications may include sinusitis, nasal polyps, liver disease, and pancreatitis. The life expectancy for individuals with cystic fibrosis, even those with milder forms, averages around 30 years. The testing associated with CPT® Code 81221 is particularly valuable for families with a known history of CFTR mutations, as it allows for the identification of specific mutations in family members, aiding in the understanding of disease severity and carrier status.